MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- OTCPINK: PETV PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is pleased to announce the addition of Mr. Michael Haider and Mr. Joel Hapke.
Michael Haider has over 40 years of medical business, finance and management experience, most recently as Co-Founder and CEO of CytoMedical Design Group LLC, a company focused on blood-based stem cell research. Haider was President and CEO of BioE LLC, BioE, Inc. and he was President and owner of Kodiak Restoration, a dental and medical equipment service company; president and co-founder of PulseTrend, Inc., a maker of ambulatory blood pressure devices; and vice president and CFO of PPT Vision, a producer of machine vision technologies. Prior to these endeavors, Haider held a variety of positions in corporate finance at Medtronic, Inc., a leading provider of medical devices. Recent Honors: He was named one of Twin Cities-based Finance and Commerce’s “Innovators of The Year” in 2003. In 2006 Minnesota Tekne Award, Emerging Biotechnology Company category and Twin Cities Business, 2007 Biosciences Success Stories. 2009 to current a member of the National Marrow Foundation (“Be the Match”) New Technology Council, since 2007 to current an annual presenter of stem cell business strategies to the University of Minnesota School of Pharmacy.
Mr. Haider commented, “I am looking forward to working with the PetVivo team toward implementing PetVivo’s vision and exciting technology toward improved patient outcomes in veterinary and future human therapies. “
Mr. Joel Hapke has over 30 years of combined experience in clinical laboratory science, medical device and diagnostic assay development. Joel has been with CytoMedical Design, LLC and BioE, Inc. for the past 18 years as the Manager of Manufacturing, Analytical and Process Engineering. Prior to coming to BioE and CytoMedical, Joel was employed by QuanTech Ltd. As the Systems Integration Coordinator, working with both engineering and chemistry personnel to develop a clinical assay platform utilizing Surface Plasmon Resonance (SPR) for a Point of Care medical device.
“The addition of Mr. Haider and Joel Hapke, working alongside our current staff in our manufacturing and research area, gives PetVivo an ability for testing, revising and innovation with little outside contracting of services. Our intension is to continue on this path, creating better manufacturing standards and efficiencies along with expanding the use of our current products.” Stated Wes Hayne, CEO.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s
lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
PetVivo Holdings, Inc.
Direct: (763) 443-7272